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Abstract   
Background: Smoking tobacco increases the risk of respiratory disease in adults and children, but 
communicating the magnitude of these effects in a scientific manner that is accessible and usable by 
public and policymakers presents a challenge. We have therefore summarised scientific data on the 
impact of smoking on respiratory diseases to provide the content for a unique resource, SmokeHaz.  
Methods: We conducted systematic reviews and meta-analyses of longitudinal studies (published to 
2013) identified from electronic databases, grey literature, and experts. Random effect meta-
analyses were used to pool the findings.  
Results: We included 216 papers. Among adult smokers, we confirmed substantially increased risks 
of lung cancer (Risk Ratio (RR) 10.92, 95% CI 8.28-14.40; 34 studies), COPD (RR 4.01, 95% CI 3.18-
5.05; 22 studies) and asthma (RR 1.61, 95% CI 1.07-2.42; 8 studies). Exposure to passive smoke 
significantly increased the risk of lung cancer in adult non-smokers; and increased the risks of 
asthma, wheeze, lower respiratory infections, and reduced lung function in children. Smoking 
significantly increased the risk of sleep apnoea, and asthma exacerbations in adult and pregnant 
populations; and active and passive smoking increased the risk of tuberculosis.   
Conclusions: These findings have been translated into easily digestible content and published on the 
SmokeHaz website (www.smokehaz.eu).  
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Introduction  
 
Tobacco smoking is the leading cause of preventable death in the European Union (EU), responsible 
for nearly 700,000 deaths every year; and around 50% of smokers die prematurely resulting in the 
loss of an average of 14 years of life (1). An estimated further 13 million people in the EU are living in 
poor health with chronic diseases as a result of smoking. Many forms of cancer, cardiovascular and 
respiratory diseases are linked to tobacco use, which causes more problems than alcohol, drugs, 
high blood pressure, excess weight or high cholesterol. Passive smoking is a significant health hazard 
to children as well as non-smoking adults, being responsible for causing excess cases of sudden 
infant death syndrome, asthma, middle ear infections, and meningitis (2). Thus, preventing smoking 
remains a key health priority. Since smoking prevention requires population-level policy measures as 
well as individual treatment interventions (3), it is important that accurate data on the effects of 
tobacco use on health are readily available to policymakers, policy advocates and the general public.   
In this respect, one major difficulty is that the available evidence on smoking and health is extensive, 
disparate and at times conflicting. Therefore, it is particularly important that the evidence base is 
regularly captured, through systematic review, and synthesised to provide easily understandable 
and accurate summary estimates of effect.  
 
This paper reports on the findings of the SmokeHaz project, which summarises the harms of smoking 
on respiratory health in a freely-accessible online resource for policy makers, researchers, students, 
healthcare professionals and the public (www.smokehaz.eu). SmokeHaz is a collaborative project 
between the UK Centre for Tobacco and Alcohol Studies, the European Respiratory Society, and the 
European Lung Foundation. In this project, all the available worldwide literature up to 2013 has been 
used to update a series of systematic reviews and meta-analyses on associations between tobacco 
smoking and a range of respiratory health outcomes. This manuscript presents the detailed scientific 
data for validation by independent peer review, and is designed to promote and strengthen public 
awareness of tobacco control issues as requested in Article 12 of the WHO Framework Convention 
on Tobacco Control (3).  
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Methods  
Inclusion Criteria 
We included longitudinal, cohort, or nested case-control studies that assessed the effect of active or 
passive tobacco smoking on the risk of developing respiratory diseases. Outcomes of interest 
included lung cancer, chronic obstructive pulmonary disease, asthma and wheeze, asthma 
exacerbations, sleep apnoea or tuberculosis in adults, and asthma and wheeze, asthma 
exacerbations, lung function, sleep apnoea, or lower respiratory tract infection in children. Where 
possible we used biochemically verified measures of smoking, for example exhaled carbon monoxide 
or saliva cotinine levels, in preference to self-reported smoking status. Active smoking was defined 
as ever smoker, current smoker, ex- or former smoker; and passive smoking was defined as being in 
contact with second hand smoke from any source; domestic, occupational, or other sources. Studies 
assessing levels of exposure to smoke based on cigarette consumption (pack years defined as 
number of packs smoked per day multiplied by number of years smoked, duration of smoking, or the 
number of cigarettes smoked per day) were also included. For passive smoking, we included studies 
which assessed effects either in non- or never-smokers or where the effect of active smoking was 
adjusted for in the statistical analyses. In addition to adult populations, studies focusing on in utero, 
infants, children and adolescents were also included. Where insufficient studies were identified for 
particular outcomes, we extended our searches to include studies reporting disease-specific 
mortality. Studies which only looked at passive smoke exposure relating to cooking fuels, and those 
looking at active or passive smoking from illegal substances were excluded. To ensure the strictest 
independence of the science as far as possible within the limits of disclosed knowledge, we omitted 
any primary studies with declared or identifiable involvement of the Tobacco Industry. 
 
Search Strategy 
Comprehensive literature searches in Medline, EMBASE and Web of Science were conducted from 
1985 to 2013 (precise end dates varied for each health outcomes), with no language restrictions 
imposed. We also searched conference proceedings from major international tobacco control 
conferences and a range of websites hosted by relevant professional societies. Contact with experts 
in the field was made to identify further relevant published or unpublished research. References lists 
of all included studies were screened to identify further potentially eligible studies.  
 
Study Selection and Data Extraction 
Titles, abstracts and full text papers identified from the searches were screened by one reviewer (LJ) 
to select relevant articles. A second reviewer (JLB) independently screened a minimum of 10% of 
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titles and abstracts and 30% of full text papers. Two authors (LJ and JLB) independently extracted 
data from included studies using previously piloted data extraction forms and independently 
assessed the quality of the included studies using the Newcastle-Ottawa Scale (4) for primary studies 
and the Assessment of Multiple Systematic Reviews (AMSTAR) Scale for existing systematic reviews 
(5). A Newcastle-Ottawa Scale score of 7 or more indicated high quality in the primary studies. 
Disagreements and discrepancies in study selection and data extraction were resolved through 
discussion. 
 
Statistical Analysis  
We extracted measures of effect for the association between exposure to smoking and the risk of 
disease using either odds ratios (OR), risk ratios (RR), hazard ratios (HR) or incidence rate ratios (IRR), 
with 95% confidence intervals (CI). Estimates adjusted for potential confounders were used in 
preference to crude estimates. Pooled Relative Risk Ratios (RR) were estimated using random effect 
meta-analyses. Heterogeneity between the studies was assessed using the I² statistic (6). Subgroup 
analyses were performed to explore reasons for heterogeneity based on gender, age of children, 
country (Europe compared to the rest of the world), methodological quality, and level of exposure 
(for example, pack-years of active smoking). Evidence of publication bias was assessed using funnel 
plots.P values<0.05 were considered statistically significant. Statistical analysis was performed using 
STATA version 11 & Review Manager 5.3. The reviews adhered to the Meta-analysis of Observational 
Studies in Epidemiology (MOOSE) (7) and the Preferred Reporting Items for Systematic Reviews and 
Meta-Analyses (PRISMA) (8) guidelines.  
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Results  
 
The main findings from the systematic reviews and meta-analyses are presented. The characteristics 
of the studies included in the systematic reviews are presented in Table 1. Tables giving more 
information about the study populations, and wider data including funnel plots and additional 
figures containing more detailed data are available at www.smokehaz.eu. 
 
Lung Cancer 
 
Active smoking 
 
Thirty-four studies assessing the effect of active smoking versus non-smoking on the development of 
lung cancer were eligible for inclusion in the review (9-42). Nineteen (56%) were deemed to be of 
high quality; and 13 were conducted in Europe.  
Smokers were 11 times more likely than non-smokers to develop lung cancer (RR 10.92, 95% CI 8.28 
to 14.40; I2=95%; 34 studies; Figure 1) (9-42). The results were similar in both the higher and lower 
quality studies. Higher risks of developing lung cancer were seen in women (12 fold increase) 
compared to men (9 fold increase); however the test for subgroup differences was not statistically 
significant (p=0.40). Studies conducted in European countries tended to show higher risks of lung 
cancer (15 fold increase) among smokers than those conducted elsewhere (9 fold increase), but not 
reaching significance (p value for subgroup differences p=0.06). All the included studies reported 
that the incidence of lung cancer was consistently greater in those with higher cigarette 
consumption. A pooled analysis in the 13 comparisons from 11 studies (9-11, 15, 24, 25, 30-32, 34, 
36) that reported pack years, found a significant dose response relationship between increasing risk 
(from 3 fold to 12 fold) of development of lung cancer with increasing exposure (<20 pack years: RR 
3; 20-40 pack years: RR 7; 40-60 pack years: RR 11; >60 pack years: RR 12).    
Passive smoking 
Fifteen studies were included in the review, which assessed the effect of passive smoking on the risk 
of lung cancer (43-57). Six (40%) were deemed to be of higher quality. The main results are based on 
data from 13 of the studies (2 studies were excluded due to using duplicate data (44, 46)).     
Exposure to passive smoke increased the risk of developing lung cancer by 1.41 fold (41%) compared 
to never smokers unexposed to passive smoke (RR 1.41, 95% CI 1.21 to 1.65; I2=0%; 13 studies; 
Figure 1) (43, 45, 47-57). Most of this evidence was based on data from woman non-smokers who 
were exposed to passive smoke from their smoker husbands (11 of the studies). Similar risks of lung 
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cancer were seen in European countries compared to studies conducted elsewhere in the world, and 
in higher quality studies compared to lower quality studies. A meta-analysis to investigate the effect 
of levels of exposure to passive smoke was possible in 4 studies (47, 50, 51, 53), which found women 
whose husbands smoked >20 cigarettes per day had a 1.46 fold (46%) increased risk of lung cancer 
compared to women with non-smoker husbands (RR 1.46, 95% CI 1.10 to 1.44; 4 studies).  
 
Chronic Obstructive Pulmonary Disease (COPD) 
Active smoking  
Twenty- four studies (58-81) assessing the effect of smoking on the risk of developing COPD were 
identified from a previous systematic review (82) and an updated search; however, only 22 of the 
studies provided sufficient data to be included in the meta-analysis. The majority (13) of the 
included studies used the GOLD criteria to define COPD based on forced expiratory volume in one 
minute (FEV1)/forced vital capacity (VC) <70%.  Only five of the studies (21%) were deemed to be of 
high quality.  
 
Smokers were 4.01 times more likely to develop COPD compared to non-smokers (RR 4.01, 95% CI 
3.18 to 5.05, I² = 87%, 22 studies; Figure 1) (58-67, 69, 71-81). Similar risks of COPD were seen 
between men and women, in higher and lower quality studies, and between studies conducted in 
Europe and the rest of the world. 
 
Passive smoking  
Three studies (71, 83, 84) assessing the effect of passive smoking on the risk of COPD were identified 
from two previous systematic reviews (85, 86) and an updated search. COPD was defined as either 
FEV1 <65%, FEV1/maximum VC <65% or percent predicted FEV1 <75%, or as a clinical diagnosis of 
acute obstructive disease. None of the studies were deemed to be of high quality.  
  
In adults, exposure to passive smoking for at least one hour per day was associated with a 1.44 fold 
(44%) increased risk of COPD compared to non-smokers (RR 1.44, 95% CI 1.02 to 2.01) (84); 
however, another study found no consistent effect of passive smoking on the development of COPD 
in non-smokers (71). Exposure to passive smoking during child and adulthood was associated with a 
1.72 fold (72%) increased risk of developing COPD in adulthood (RR 1.72, 95% CI 1.31 to 2.23); 
however, no increased risk was seen in those only exposed during childhood (83).  
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Adult Asthma  
Eight studies (87-94) assessing the effect of active smoking on the risk of asthma in adults were 
identified from a previous systematic review (95). Asthma was ascertained through physician reports 
in the majority of studies, while 2 studies relied on self-reports. Four of the studies (50%) were 
deemed to be of high quality. All but 2 of the included studies (90, 94) were conducted in Europe. 
Smokers were 1.61 times (61%) more likely to develop asthma when compared to adults who had 
never smoked (RR 1.61, 95% CI 1.07 to 2.42; I2=91%; 8 studies; Figure 1) (87-94). The high level of 
heterogeneity appeared to be related to a low quality study (90), which reported a significantly 
reduced risk of asthma in smokers. A sensitivity analysis excluding this study (90) found smokers 
were 1.81 times (81%) more likely to develop asthma when compared to people who never smoked 
(RR 1.81, 95% CI 1.37 to 2.38; I2= 68%; 7 studies). The risk of developing asthma from active smoking 
was similar between European and non-European studies and between higher and lower quality 
studies. 
 
Asthma Exacerbations  
Five studies (96-100) were identified for inclusion which assessed the effect of active and passive 
smoking on exacerbations of asthma in adults, pregnant women or children. Three of the studies 
(60%) were deemed to be of high quality.  
Active smoking 
Two studies assessed the effect of active smoking on asthma exacerbations (96, 97). Adults with 
asthma who were current or ex-smokers had a 1.71 times higher risk of subsequent asthma 
exacerbations than adults with asthma who had never smoked (RR 1.71, 95% CI 1.48 to 1.97, 1 
study) (96). A study of 80 pregnant women with asthma found that being a current smoker or ex-
smoker significantly increased the number of severe asthma exacerbations per year, and being a 
current smoker also resulted in poorer asthma control, compared to those who never smoked (97). 
Passive smoking  
Three studies assessed the effect of passive smoking on asthma exacerbations (98-100). In non-
smoking adults, exposure to passive smoke significantly increased the risk of being restricted in daily 
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activities (RR 1.61, 95% CI 1.06 to 2.46, 1 study) (99), but had no significant effect on increased risks 
of cough, shortness of breath or being awakened by asthma (90), or on admission to hospital for 
asthma (98). In a study of 140 children with asthma aged 3-15 years, exposure to passive smoke in 
the household or by the mother more than doubled the risk of multiple hospital admissions for 
asthma per year (RR 2.55, 95% CI 1.12-5.82; 1 study) and exposure to maternal smoking more than 
tripled the risk of multiple hospital admissions for asthma per year (RR 3.25, 95% CI 1.13-8.85) (100).  
 
Tuberculosis (TB) 
Five studies (101-105) assessing the effect of active and passive smoking on the risk of developing TB 
were identified from 4 previous systematic reviews (106-109) and an updated search. Four of the 
studies (80%) were deemed to be of high quality. None of the studies were conducted in Europe 
Active smoking 
Four studies assessed the effect of active smoking (101-104). People who smoked were 1.57 times 
(57%) more likely to develop TB when compared to those who had never smoked (RR 1.57, 95% CI 
1.18 to 2.10; I2=93%; 4 studies; Figure 1). Significantly higher risks of TB from smoking were seen the 
higher quality studies (2.2 times) compared to the study with a lower quality (1.1 times) (test for 
subgroup differences, p<0.00001); however similar risks were seen in studies of men and women. All 
of the studies reported an increased risk of TB with increasing numbers of cigarettes smoked per 
day.  
Passive smoking 
Two studies assessed the effect of passive smoking (103, 105). Exposure to household tobacco 
smoke increased the risk of developing TB by 1.44 times (44%) compared to people who were 
unexposed to household tobacco smoke (RR 1.44, 95% CI 1.02 to 2.04; I2=0%; 2 studies). Both of the 
included studies were deemed to be of high quality, and similar results were seen for males and 
females. However, no significant trend was seen between the increased frequency of exposure to 
passive smoke (numbers of days per week exposed) and the risk of TB (p=0.74) (103). 
  
Sleep Apnoea    
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Five studies (110-115) assessing the effect of active and passive smoking on the risk of sleep apnoea 
were identified from a previous review (116) and an updated search. None of the included studies 
were deemed to be of high quality.  
 
Active smoking 
Three studies assessed the effect of active smoking on the development of sleep apnoea in adults 
(111, 112, 115). Two of these studies reported numerical data, which found that people who smoke 
are twice as likely to have sleep apnoea than those that do not smoke (RR 1.97, 95% CI 1.02 to 3.82; 
2 studies) (112, 115). Men and women were found to have similar risks of sleep apnoea from 
smoking (1.5 fold increase) when compared with non-smokers (115). One study investigated 
intensity of exposure and found a dose-dependent relationship where the greatest risk of sleep 
apnoea was associated with smoking at least 40 cigarettes per day (RR 8.38, 95% CI 1.68 to 41.94, 1 
study) (112).   
Passive smoking 
Two studies assessed the effect of passive smoking on the risk of development of sleep apnoea in 
infants or young children (113, 114). Maternal smoking during pregnancy approximately doubled the 
risk of their infant developing sleep apnoea (age range from 1 day – 29 weeks) (RR 1.76, 95% CI 1.17 
to 2.64, 1 study) (113). Maternal smoking after birth significantly increased the risk of developing 
sleep apnoea in children aged 6-18 months (RR 1.25, 95% CI 1.06 to 1.47, 1 study) (114). One study 
(113) also reported significantly more infants developed sleep apnoea where both parents had 
smoked during pregnancy compared to only mothers smoking during pregnancy (p=0.007). 
 
Lower Respiratory Tract Infections (LRTI) in Childhood 
Thirty-four studies (117-150) assessing the effect of passive smoking on the risk of LRTI in children 
under 2 years were identified from a previous review (151) and an updated search. Eighteen studies 
considered the effects of any household member smoking, six of both parents smoking, nine of 
paternal smoking, 16 of maternal smoking, and 11 of pre-natal maternal smoking (some studies 
covered more than one exposure). Sixteen (47%) were deemed to be of high quality, and 17 were 
conducted in Europe.   
Infants exposed to smoking by any household member were 1.43 times (43%) more likely to develop 
LRTI compared to those not exposed to smoking in the home (RR 1.43, 95% CI 1.28 to 1.59; I2=45%; 
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18 studies; Figure 2). Similar risks of LRTI were seen in European studies (1.42 times) and non-
European studies (1.46 times), and in higher (1.49 times) and lower (1.35 times) quality studies. 
Significant increased risks of developing LRTI were also seen in Infants exposed to both parents 
smoking (RR 1.82, 95% CI 1.51 to 2.19; I2=45%; 6 studies), prenatal maternal smoking (RR 1.19, 95% 
CI 1.10 to 1.29; I2=78%; 11 studies), maternal smoking in the postnatal period (RR 1.62, 95% CI 1.46 
to 1.79; I2=50%; 16 studies), but not to paternal smoking (RR 1.15, 95% CI 0.97 to 1.36; I2=51%; 9 
studies). 
Childhood Asthma and Wheeze  
Seventy-one studies assessing the effect of passive smoking in the risk of developing asthma or 
wheeze in childhood were identified from a recent systematic review (152). Thirty-one of the studies 
(44%) were deemed to be of high quality, and 32 were conducted in Europe.  
Wheeze in childhood 
Children aged ≤2 years who had been exposed to prenatal maternal smoking had a 1.41 times (41%) 
increased risk of developing wheeze compared to unexposed children (RR 1.41, 95% CI 1.19 to 1.67; 
Figure 3). Similar effects were observed for the relationship between prenatal maternal smoking and 
the incidence of wheeze in children aged 3 to 4 years (1.28 times) and 5 to 18 years (1.52 times). 
Similar effect sizes were seen in children aged 5-18 years who were exposed to paternal smoking 
(1.39 times) and in children exposed to household tobacco smoke (1.32 times). 
The strongest impact on the incidence of wheeze was seen in children exposed to postnatal 
maternal smoking, where children under 5 years exposed to postnatal maternal smoking were 1.65 
to 1.70 times (65-70%) more likely than unexposed children to develop wheeze (≤2 years: pooled RR 
1.70, 95% CI 1.23 to 2.35; 3 to 4 years: RR 1.65, 95% CI 1.20 to 2.27).   
For all sources of exposure to smoking (prenatal, postnatal, paternal, household), the effect size for 
the increased risk of wheeze were similar in sensitivity analyses based methodological quality and 
geographical location of the studies; except for the following sensitivity analyses: In European 
studies, the magnitudes of the risks of wheeze from prenatal maternal smoking in children aged 2 
years or younger were larger (2.21 times) compared to all studies (1.41 times). For children aged 3-4 
years, a larger magnitude of risk of household smoking on the risk of wheeze was seen in higher 
quality studies (1.20 times) compared to all studies (1.06 times).  
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Asthma in childhood 
Children aged ≤2 years who were exposed to prenatal maternal smoke were 1.85 times (85%) more 
likely to develop asthma compared to unexposed children (RR 1.85, 95% CI 1.35 to 2.54; Figure 4). 
However, smaller magnitudes of risk were seen in children aged 3-4 years (1.30 times) and those 
aged 5-18 years (1.23 times). Across the age groups, children exposed to household smoking were 
1.14 to 1.30 times (14-30%) more likely to develop asthma. However, exposure to postnatal 
maternal or paternal smoke did not appear to consistently increase the risk of developing asthma in 
any age group.   
For all sources of exposure to smoking (prenatal, postnatal, paternal, household), the effect size for 
the increased risk of asthma were similar in sensitivity analyses based methodological quality and 
geographical location of the studies; except for the following sensitivity analyses: In European 
studies, the magnitudes of the risks of asthma from postnatal maternal smoking in children aged 5-
18 years were larger (1.48 times) compared to all studies (1.20 times). In children aged 5-18 years, 
the magnitude of the risk of asthma from exposure to household smoking was larger (2.02 times) 
compared to all studies (1.30 times).  
 
 
Lung Function in Childhood  
 
Infants 
Thirteen studies (153-165) assessing the effect of exposure to passive smoking on lung function in 
infants were identified from a previous review (2) and an updated search. Lung function 
measurements were assessed within 8 weeks of birth in all studies. Seven studies were conducted in 
Europe.  
Pre-natal exposure: Seven of the studies assessed the effect of prenatal exposure of infants to 
maternal smoking on maximal flow at functional residual capacity (FRC), with the majority finding no 
significant reductions (154, 158, 159, 161, 165). However, the two remaining studies found prenatal 
maternal smoking significantly reduced maximal flow at FRC (157, 164). Prenatal maternal smoking 
had no significant effect on FRC at 8 weeks of age (155). Prenatal maternal smoking was significantly 
associated with reduced tidal breathing ratio (tPTEF:tE) in the infants within one week following 
birth (162) and in those born preterm at 37 weeks gestation (158), but no association between tidal 
breathing ratio in infants and maternal smoking was seen in the other studies (154-156). No 
apparent effect of prenatal smoking was seen on infant respiratory system compliance (CRS) (155, 
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156, 158, 164), except for one study were CRS was reduced in boys but not girls (160). Prenatal 
maternal smoking reduced lung function (FEV0.5), in infants at 6 weeks of age (153). 
Post-natal exposure:  Postnatal maternal smoking significant reduced airflow during inspiration and 
expiration in their infants as measured by specific conductance, hence potentially increased 
susceptibility to asthma and/or COPD (156). However, maternal postnatal smoking was not 
associated with bronchial responsiveness in their infants (153, 154) or a reduction in lung volume 
(155, 157, 160). Paternal smoking during pregnancy had no significant impact on various measures 
of lung function (tidal volume, respiratory rate, minute ventilation and time to peak expiratory flow) 
(163). 
 
School-aged children 
Twelve studies (166-177) assessing the effect of passive smoking on lung function in school-aged 
children were identified from a previous review (2) and an updated search. None of the studies were 
deemed to be of high quality, and only four were conducted in Europe. 
Pre-natal exposure: Individual studies found smoking during pregnancy was significantly associated 
with the children having a 62 ml reduction in FEV1 and 53 ml reduction in FVC at age 5 years (173), 
and significantly lowered peak expiratory flow at age 8 years (166); however, no significant effect on 
lung function was seen in other studies (167, 170). 
Post-natal exposure: Any parental smoking significantly reduced FEV/FVC ratios by 0.67% and FEF25-
75 by 2%, and significantly increase FVC by 0.58%, but had no effect on FEV1 (2 studies; Figure 5) (170, 
177). Data from individual studies showed postnatal maternal smoking had no significant effect on 
measures of lung function (166, 171, 172, 175); however, continual maternal smoking during and 
after pregnancy significantly reduced some measures of lung function (FEV/FVC and FEF25-75), with 
similar magnitudes of reductions seen in boys and girls (170). Furthermore, both parents smoke 
resulted in significantly lower FEV1/FVC ratios in boys, but not in girls; but no effect was seen for only 
exposure to paternal smoking (175). In another study, exposure to smoke measured using cotinine 
levels in hair resulted in significant decreases in PEF, but not FEV1 (174).  
Three of the included studies assessed the effect of exposure to smoking on lung growth (168, 169, 
176); however, no consistent effect of parental or household smoking on lung function assessment 
of lung growth was demonstrated. Exposure to household smoking resulted in a significant increase 
in the growth by 7 ml in girls, but significantly reduced growth by 12 ml in boys (168). Having both 
parents smoke resulted in a significant reduction in lung growth in children aged 8-9 years, but no 
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effect was seen at older ages or in those with one parental smoker (169). However in another study, 
maternal smoking significantly reduced the expected annual lung growth (176). 
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Discussion  
After decades of public scepticism amongst tobacco smokers, this millennium has seen major 
advances in public awareness that tobacco smoking poses a risk to health due to highly successful 
tobacco control policies and public information campaigns (3, 178-180). However, the battle to 
ensure the public fully understand the health risks of tobacco smoking is far from won. The public 
and policymakers are well aware that lung cancer is one of the greatest risks of tobacco smoking. 
However, there is little awareness of the risk of other diseases from active and passive smoking and 
few parents understand the damage their smoking can do to their children (179). This lack of 
knowledge remains a major challenge for policymakers. Without full understanding of the risks, 
smokers are less likely to have the motivation to quit even when effective smoking cessation 
measures are readily available (181, 182).  
The data presented in our manuscript provides policymakers, the public, and health professionals 
with an easy ‘one-stop shop’ where they can find evidence-based meta-analyses of pooled data from 
studies published to 2013, on the relationship between tobacco smoking and increased risks of 
respiratory diseases in adults and in children. The main findings from our updated systematic 
reviews and meta-analyses are discussed below. 
As previously mentioned, it is recognised that the public know smoking increases the risk of lung 
cancer (1); but they have little knowledge of the level of the risk, where smokers are 11 times more 
likely to develop lung cancer, and there is no safe minimum number of cigarettes per day. More 
education and publicity is needed to increase public awareness of these very high risks. Exposure to 
passive smoke increased the risk of lung cancer in non-smokers by 1.41 times. Raising public 
awareness about the disease of lung cancer is also important since motivation to quit may be 
improved through better awareness and knowledge about the symptoms of lung cancer; the lack of 
a curative treatment; the catastrophic effect on life expectancy with only 12.6% of patients being 
alive 5 years after diagnosis; and that lung cancer is now the leading cause of cancer deaths 
worldwide in both men and women (180).  
It is estimated that 40-50% of life-long smokers will develop COPD (180); however, the exact 
mechanism by which tobacco smoking causes or promotes COPD is not known. Furthermore, the 
general public have little knowledge of this disease and its increased risk due to smoking. We found 
smokers are 4.01 times more likely to develop COPD, and non-smokers exposed to passive 
smoking had 1.44 to 1.72 fold increased risk of developing COPD. However, the latter finding is only 
based on data from three studies; therefore, more research is needed to better define the 
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relationship between passive smoking and the risk of development of COPD; and to establish 
whether there are differential effects based on whether passive smoke exposure occurs in 
childhood or adulthood.  
Tobacco smoking is not generally thought of as a risk factor for asthma; therefore, the public should 
be made aware that adult smokers are 1.61 times more likely to develop asthma; and adult 
smokers are 1.71 times more likely to have asthma exacerbations. We found pregnant women 
with asthma who smoke have more asthma exacerbations per year and poorer asthma control; 
and children exposed to passive smoke are more than twice as likely to have multiple hospital 
admissions. 
Although there has been a major reduction in the prevalence and incidence of TB in past decades, 
the threat of TB is now growing once again because of the emergence of new strains that are 
resistant to anti-TB drugs. With the inevitable threat of multi-drug resistant TB increasing across 
Europe, it is important for policymakers to learn of any preventative measures, large or small, that 
might contribute to reducing this emerging new threat. Therefore, it is important that we highlight 
the need to raise public awareness in relation to our findings that: i) adults smokers are 1.57 times 
more likely to develop TB; ii) the risk of TB increases with increasing consumption of cigarettes per 
day for a longer period of time; and iii) non-smokers who are exposed to passive smoke have a 
1.44 times increased risk of developing TB. This evidence provides a motivator to ensure effective 
smoking-cessation programmes are provided for populations who live in regions identified as at 
especially high risk of TB.    
The role of smoking on the risk of sleep apnoea is currently unclear. We found adult smokers were 
1.97 times as likely to develop sleep apnoea, and the risk could be as great as 8.38 times where at 
least 40 cigarettes are smoked per day. We also found maternal smoking during pregnancy 
increased the risk of sleep apnoea in infants by 1.76 times; and postnatal maternal smoking 
increases the risk of sleep apnoea in childhood by 1.25 times. Our review indicates that smoking is 
a significant contributory factor to sleep apnoea, but the evidence base is limited and needs 
strengthening. Therefore, efforts should be made to increase public awareness of the link between 
smoking and sleep apnoea.  
 
Lower respiratory tract infections (LRTI) are an especial problem in childhood (180). We found the 
risk of infants developing LRTI was significantly increased from their exposure to passive smoking 
within the household; where the largest increase in risk, 1.82 fold, was from both parents 
smoking. We also found prenatal exposure to maternal smoking increased the risk of LRTI by 1.19 
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fold. Policymakers are already aware of the harm passive smoking can do to children, and they 
should be informed that smoke-free legislation has already led to a decrease in passive smoke 
exposure with a corresponding reduction in hospital admissions of children with respiratory tract 
infections (183). 
Regarding childhood asthma and wheeze, exposure to passive smoking in the home environment 
significantly increased the risk of developing asthma and/or wheeze, where the largest increases 
in risk seemed to be from maternal prenatal smoking on asthma in infants under 2 years (1.85 
fold) and maternal postnatal smoking on wheeze in children under 5 years (up to 1.70 fold). The 
findings indicate that passive smoking has a greater effect on the risk of wheeze in children across all 
age groups than on the risk of asthma, where children under 2 years old are at greater risk. More 
research is needed to understand the mechanisms underlying these effects and the components of 
tobacco smoke involved. It is encouraging that adoption of comprehensive smoke-free legislation 
has led to a significant reduction in the rate of hospital admissions for childhood asthma (184). 
Regarding lung function, we found exposure to passive smoking can decrease lung function in 
infants within 8 weeks of birth and in school-aged children. The findings of these studies were 
variable and most lung function measurements were normal. The only findings of note were that 
exposure of infants to maternal smoking after birth is associated with reduced airflow, which may 
reflect the reported increased susceptibility of children to the various airways diseases discussed 
above; and that maternal smoking during pregnancy and parental smoking after birth may have a 
detrimental effect on lung function in school-aged children. However, there is currently insufficient 
evidence to reach firm conclusions on the effect of prenatal and postnatal parental smoking on lung 
function of their children.  
The strength of our systematic reviews is that methodological quality of the evidence within the 
systematic reviews was generally good, with the majority of the more recent studies providing 
adjusted effect estimates, thereby reducing the potential for confounding within our pooled 
estimates. We are confident that our search strategies were comprehensive and we were able to 
identify further eligible studies through contact with experts with an interest in tobacco control   
within the respiratory medicine field. A limitation of the systematic reviews relates to the high levels 
of heterogeneity found within some comparisons; however, we performed exploration analyses 
using subgroup and sensitivity analyses to assess whether the association varied by participant level 
characteristics (age and gender) and study level characteristics (geographical location and 
methodological quality); and found relatively consistent findings across these subgroups.  
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In conclusion, the SmokeHaz study provides a useful resource enabling policymakers and others to 
rapidly view the available evidence-based scientific data on the increased risk of development of 
respiratory diseases in adults and children caused by active and passive tobacco smoking. The high 
levels of risk reported support smoke-free legislation, and justify its continuance and expansion, not 
only in public places, but also in the home and other confined spaces, such as cars, to protect 
children. All governmental efforts against smoking should be strengthened, with the ultimate aim of 
phasing-out tobacco use. Because of the now indisputable health hazards, measures to help all 
current smokers to quit should be widely available to the general public, and to patients suffering 
from smoking related diseases ensuring cost is not a barrier. Education to disseminate information 
to increase public awareness of the many health risks of smoking should be improved; and education 
and training on the health risks and in smoking cessation methods should be included in the 
curricula of all health professionals and medical students. The SmokeHaz systematic review of 
respiratory health risks of smoking, and its companion free public website (www.smokehaz.eu), are 
ideal as educational resources since they aim to promote and strengthen public awareness of 
tobacco control issues, thus complying with Article 12, ‘Education, communication, training and 
public awareness’, of the WHO Framework Convention on Tobacco Control (3). 
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Table legends 
Table 1  Characteristics of studies included in the systematic reviews 
 
Figure legends 
 
Figure 1 Summary estimates from meta-analyses assessing the effect of active and passive 
smoking on the risk of lung cancer, COPD, asthma, sleep apnoea, and tuberculosis in 
adults 
Figure 2 Summary estimates from meta-analysis assessing the effect of passive smoking on 
the risk of lower respiratory tract infection in infants  
Figure 3 Summary estimates from meta-analyses assessing the effect of exposure to passive 
smoking on the risk of developing wheeze in children 
Figure 4 Summary estimates from meta-analyses assessing the effect of exposure to passive 
smoking on the risk of developing asthma in children 
Figure 5 Meta-analysis for the effect of passive smoke exposure on lung function in school-
aged children 
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Table 1  Characteristics of studies included in the systematic reviews 
Diseases Tobacco 
smoking 
Number of 
studies 
References Used a cohort 
design 
Conducted in 
Europe 
Assessed as 
high quality 
Published 
since 2000 
Adult: 
Lung cancer Active 34 [9-42] 27 (79%) 13 (38%) 19 (56%) 22 (65%) 
Passive 15 [43-57] 13 (91%) 4 (27%) 6 (40%) 8 (53%) 
COPD Active 24 [58-81] 22 (92%) 15 (63%) 5 (21%) 20 (83%) 
Passive 3 [71, 83, 84] 3 (100%) 1 (33%) 0 (0%) 0 (0%) 
Asthma Active 8 [87-94] 8 (100%) 6 (75%) 4 (50%) 3 (38%) 
Asthma exacerbations Active 2 [96-97] 1 (50%) 1 (50%) 2 (100%) 2 (100%) 
Passive 3 [98-100] 3 (100%) 2 (67%)† 1 (33%) 2 (67%) 
Tuberculosis Active 4 [101-104] 4 (100%) 0 (100%) 3 (75%) 4 (100%) 
Passive 2 [103, 105] 2 (100%) 0 (100%) 2 (100%) 2 (100%) 
Sleep apnoea Active 3 [111-112, 115] 3 (100%) 2 (67%) 0 (0%) 1 (33%) 
Passive 2 [113-114] 2 (100%) 2 (100%) 0 (0%) 1 (50%) 
Childhood: 
LRTI Passive 34 [117-150] 34 (100)% 17 (50%) 16 (47%) 16 (47%) 
Asthma/wheeze Passive 71 [152] 71 (100%) 32 (45%) 31 (44%) 55 (77%) 
Lung function in infants Passive 13 [153-165] 13 (100%) 7 (57%) 6 (46%)‡ 5 (38%) 
Lung function in school-
aged children 
Passive 12 [166-177] 12 (100%) 4 (33%) 0 (0%) 6 (50%) 
COPD Chronic Obstruc]ve Pulmonary Disease; LRTI Lower Respiratory Tract Infec]on; †one study was conducted in both the UK and US; ‡assessed based on adjustment 
for confounders 
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Abbreviations 
COPD Chronic Obstructive Pulmonary Disease 
CI Confidence Interval 
CRS Respiratory System Compliance  
EU European Union 
FEF25-75 Forced Expiratory Flow during the mid-portion of the FVC 
FEV1 Forced Expiratory Volume in one second 
FRC Functional Residual Capacity  
FVC Forced Vital Capacity 
LRTI Lower Respiratory Tract Infection 
PEF Peak Expiratory Flow 
RR Risk Ratio 
 
